Ixabepilone is primarily used in the treatment of metastatic or locally advanced breast cancer, particularly in cases where other treatments, such as anthracyclines and taxanes, have proven ineffective. It works by stabilizing microtubules, which inhibits cell division and ultimately leads to cancer cell death. This makes it a valuable option for patients with resistant or refractory breast cancer. It is often administered intravenously and may be used as a monotherapy or in combination with other chemotherapeutic agents like capecitabine. Its application is carefully monitored due to potential side effects, including neuropathy, myelosuppression, and hypersensitivity reactions.